CU20250001A7 - Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos - Google Patents

Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos

Info

Publication number
CU20250001A7
CU20250001A7 CU2025000001A CU20250001A CU20250001A7 CU 20250001 A7 CU20250001 A7 CU 20250001A7 CU 2025000001 A CU2025000001 A CU 2025000001A CU 20250001 A CU20250001 A CU 20250001A CU 20250001 A7 CU20250001 A7 CU 20250001A7
Authority
CU
Cuba
Prior art keywords
obicetrapib
salts
manufacture
processes
intermediate products
Prior art date
Application number
CU2025000001A
Other languages
English (en)
Inventor
Christopher J Borths
Sheng Cui
Muneki Kishida
Andreas René Rötheli
Valeriya Nikolayevna Smolenskaya
Original Assignee
Newamsterdam Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newamsterdam Pharma B V filed Critical Newamsterdam Pharma B V
Publication of CU20250001A7 publication Critical patent/CU20250001A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

<p>Se proporciona en el presente documento un método para la fabricación de un compuesto de obicetrapib y sales de este, tales como sales de calcio de este. También se proporciona en el presente documento hemicalcio de obicetrapib amorfo. También se proporcionan nuevos productos intermedios para usar en la síntesis de obicetrapib, y sales de este, incluido obicetrapib HCI y una sal de mesilato para usar en la síntesis de obicetrapib y hemicalcio de obicetrapib amorfo.</p>
CU2025000001A 2022-07-05 2023-07-03 Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos CU20250001A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263358363P 2022-07-05 2022-07-05
PCT/IB2023/000392 WO2024009144A1 (en) 2022-07-05 2023-07-03 Salts of obicetrapib and processes for their manufacture and intermediates thereof

Publications (1)

Publication Number Publication Date
CU20250001A7 true CU20250001A7 (es) 2025-10-17

Family

ID=87889756

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2025000001A CU20250001A7 (es) 2022-07-05 2023-07-03 Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos

Country Status (19)

Country Link
US (3) US12006305B2 (es)
EP (1) EP4551567A1 (es)
JP (1) JP2025524532A (es)
KR (1) KR20250049276A (es)
CN (1) CN119013267A (es)
AR (1) AR129814A1 (es)
AU (1) AU2023303916A1 (es)
CA (1) CA3261180A1 (es)
CL (1) CL2025000016A1 (es)
CO (1) CO2025001010A2 (es)
CR (1) CR20250038A (es)
CU (1) CU20250001A7 (es)
IL (1) IL317973A (es)
JO (1) JOP20240290A1 (es)
MA (1) MA71399A (es)
MX (1) MX2025000257A (es)
PE (1) PE20251749A1 (es)
TW (1) TW202409008A (es)
WO (1) WO2024009144A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4294387A1 (en) * 2021-02-18 2023-12-27 NewAmsterdam Pharma B.V. Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia
WO2025059594A1 (en) 2023-09-15 2025-03-20 Newamsterdam Pharma B.V. METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
WO2025146415A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
WO2026062050A1 (en) 2024-09-17 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
WO2026063944A1 (en) * 2024-09-21 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for the treatment of dementias
WO2026062049A1 (en) * 2024-09-21 2026-03-26 Newamsterdam Pharma B.V., Obicetrapib for the treatment of dementias

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT54991A (en) 1989-08-11 1991-04-29 Ici Plc Process for producing quinoline derivatives and pharmaceutical compositions comprising such compounds
GB9010394D0 (en) 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP4531027B2 (ja) 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
WO2014178040A1 (en) * 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
DK3102212T3 (en) 2014-02-05 2019-02-11 Dezima Pharma B V Cholesteryl ester transfer protein (CETP) inhibitors and pharmaceutical compositions comprising the inhibitor for use in the treatment or prevention of cardiovascular disease
EA034357B1 (ru) 2014-08-12 2020-01-30 Дезима Фарма Б.В. Способ получения синтетических промежуточных соединений для получения производных тетрагидрохинолина
US10300059B2 (en) 2014-08-28 2019-05-28 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
WO2017023166A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
CA3108437A1 (en) 2018-08-09 2020-02-13 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes
EP4294387A1 (en) 2021-02-18 2023-12-27 NewAmsterdam Pharma B.V. Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia
EP4125911B1 (en) 2021-03-05 2024-04-24 NewAmsterdam Pharma B.V. Obicetrapib for treatment of dementias
IL310115A (en) 2021-07-26 2024-03-01 Newamsterdam Pharma B V Treatment of his hyporesponders
AU2022425078A1 (en) 2021-12-30 2024-08-08 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2024226537A1 (en) * 2023-04-24 2024-10-31 Newamsterdam Pharma B.V. Amorphous obicetrapib and sglt2 inhibitor combination

Also Published As

Publication number Publication date
TW202409008A (zh) 2024-03-01
IL317973A (en) 2025-02-01
PE20251749A1 (es) 2025-07-09
EP4551567A1 (en) 2025-05-14
US12006305B2 (en) 2024-06-11
JOP20240290A1 (ar) 2024-12-26
US12378221B2 (en) 2025-08-05
AU2023303916A1 (en) 2025-01-30
JP2025524532A (ja) 2025-07-30
AR129814A1 (es) 2024-10-02
US20250296921A1 (en) 2025-09-25
CL2025000016A1 (es) 2025-04-21
MA71399A (fr) 2025-04-30
CN119013267A (zh) 2024-11-22
MX2025000257A (es) 2025-03-07
KR20250049276A (ko) 2025-04-11
CA3261180A1 (en) 2024-01-11
CO2025001010A2 (es) 2025-04-28
US20240010630A1 (en) 2024-01-11
US20240391897A1 (en) 2024-11-28
WO2024009144A1 (en) 2024-01-11
US12570628B2 (en) 2026-03-10
CR20250038A (es) 2025-05-26

Similar Documents

Publication Publication Date Title
CU20250001A7 (es) Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos
CY1120080T1 (el) Φαρμακευτικη συνθεση περιεχουσα εναν αναστολεα hdac και εναν κυκλοπολυσακχαριτη
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
MX2017000926A (es) Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble.
UY33815A (es) Composiciones y métodos para modular el fxr
CY1114689T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CL2024003553A1 (es) Proceso e intermediarios para preparar un inhibidor de jak.
SV2011003846A (es) Polimorfo b de la n-(2-aminofenil)-4- [n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
MX2025003091A (es) Metodo para producir derivado de heterociclideno acetamida
EA201290872A1 (ru) Способ получения бензоксаборолов
PE20191103A1 (es) Inhibidores de dopamina-b-hidroxilasa
ECSP13013026A (es) Isoxazolinas como agentes terapéuticos
JOP20210312A1 (ar) أملاح مقبولة صيدلانياً من [2-(3- فلورو-5- ميثان سلفونيل فينوكسي) إيثيل ](بروبيل) أمين واستخداماتها
CL2021001640A1 (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
EA201391206A1 (ru) Способы синтеза производных предшественника молибдоптерина z
CU20250003A7 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
EA202192731A1 (ru) СПОСОБ ПОЛУЧЕНИЯ АКСИТИНИБА, СПОСОБ ОЧИСТКИ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ 2-((3-ЙОД-1H-ИНДАЗОЛ-6-ИЛ)ТИО)-N-МЕТИЛБЕНЗАМИДА, СПОСОБ ОЧИСТКИ АКСИТИНИБА ЧЕРЕЗ HCl СОЛЬ АКСИТИНИБА, ТВЕРДАЯ ФОРМА HCl СОЛИ АКСИТИНИБА
CL2012000270A1 (es) Procedimiento de preparacion de ivabradina y de sus sales de adicion por formacion del anillo benzoacepino; y los compuestos intermediarios considerados en el procedimiento.
MX2018004631A (es) Proceso industrial para la preparación de la sal de (e)-3-carboxiacrilato de (5s,10s)-10-bencil-16-metil-11,14,18-trio xo-15,17,19-trioxa-2,7,8-tritia-12-azahenicosan-5-aminio.
MX2024010402A (es) Inhibidores de proteinas de union a emopamilo y usos de estos
FR2970000B1 (fr) Nouveau procede de synthese de l&#39;agomelatine